多替阿巴拉米片是医保药吗？

Five months after receiving formal approval from the State Food and Drug Administration (CFDA), the British pharmaceutical company GlaxoSmithKline (GSK) recently announced that its joint venture ViiV Healthcare’s new anti-AIDS drug Suimeikai (chemical name:) has been officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Suimeikai is composed of three ingredients: DTG (DTG) + Abacavir (ABC) + Lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating. In 2016, GSK launched the integrase DTG (Trivic) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. This time, Trimic uses DTG, an integrase inhibitor, as the core drug, combined with a treatment plan of two backbone drugs, abacavir and lamivudine, and made a single-tablet treatment for promotion, making great progress in the core drug in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

Is Abalami Tablets a medically insured drug in the country?

According to Medical Companion Travel, it has just been launched in China and has not yet been included in medical insurance. It is not yet a medical insurance drug. Since Dolutegra is an imported original drug in China, it is very expensive and most patients cannot afford it. Therefore, many patients choose Dolutegra abalami tablets, which are available in India. Inbec, produced by the Indian company Emcure, has a box of 30 tablets and sells for about RMB 1,000. Due to the floating exchange rate, the price cannot be determined. Please consult Medical Travel for specific prices.